A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging

INTRODUCTION: Changes in cerebrospinal fluid (CSF) tau and amyloid β (Aβ)42 accompany development of Alzheimer's brain pathology. Robust tau and Aβ42 immunoassays were developed to establish a tau/Aβ42 cutoff distinguishing mild-to-moderate Alzheimer's disease (AD) subjects from healthy el...

Descripción completa

Detalles Bibliográficos
Autores principales: Mo, Yi, Stromswold, Julie, Wilson, Kimberly, Holder, Daniel, Sur, Cyrille, Laterza, Omar, Savage, Mary J., Struyk, Arie, Scheltens, Philip, Teunissen, Charlotte E., Burke, James, Macaulay, S. Lance, Bråthen, Geir, Sando, Sigrid Botne, White, Linda R., Weiss, Christy, Cowes, Arturo, Bush, Michele M., DeSilva, Ganga, Darby, David G., Rainey-Smith, Stephanie R., Surls, Jackie, Sagini, Eileen, Tanen, Michael, Altman, Amy, Luthman, Johan, Egan, Michael F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
CSF Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357677/
https://www.ncbi.nlm.nih.gov/pubmed/28349119
http://dx.doi.org/10.1016/j.dadm.2017.02.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357677/
https://www.ncbi.nlm.nih.gov/pubmed/28349119
http://dx.doi.org/10.1016/j.dadm.2017.02.004

Ejemplares similares